{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-004587","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.856018+00:00","generated_at":"2026-05-28T03:10:22.343895+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Ultragenyx preliminary 2024 revenue $555-560M above guidance; 2025 guide $640-670M","bullets":["Preliminary 2024 total revenue $555-560M, exceeding top end of guidance, ~29% YoY growth.","Crysvita revenue $405-410M (+24% YoY); Dojolvi revenue $87-89M (+25% YoY).","2025 total revenue guidance $640-670M; cash and investments ~$745M as of Dec 31, 2024.","UX143 Phase 3 OI study second interim analysis mid-2025; GTX-102 Phase 3 Angelman enrollment completion H2 2025.","UX111 BLA submitted (PDUFA H2 2025); DTX401 BLA filing mid-2025; DTX301 Phase 3 enrollment early 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-004587","json":"https://secwatch.observer/filing/0000950170-25-004587.json","markdown":"https://secwatch.observer/filing/0000950170-25-004587.md","text":"https://secwatch.observer/filing/0000950170-25-004587.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025004587/0000950170-25-004587-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025004587/rare-20250112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:10:22.343895+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}